Redhill Biopharma (STU:2RH) Net Income (Continuing Operations): €-6.95 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2RH Redhill Biopharma Ltd STU:2RH
18 GF Score
Price €8.24
! 6 Warning Signs
View Full Analysis

What is Redhill Biopharma Net Income (Continuing Operations)?

Redhill Biopharma STU:2RH 18 Net Income (Continuing Operations) is €-6.95 Mil as of Dec. 2025. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Redhill Biopharma's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was €-3.37 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.95 Mil.

Redhill Biopharma  (STU:2RH) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Redhill Biopharma Net Income (Continuing Operations) Related Terms

Redhill Biopharma Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Redhill Biopharma's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma Net Income (Continuing Operations) Chart

Redhill Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -86.50 -67.66 -16.96 0.34 -6.90

Redhill Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.73 -2.87 3.29 -3.58 -3.37
STU:2RH
18GF Score
Redhill Biopharma Ltd STU:2RH
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Redhill Biopharma Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €-6.95 Mil mean?
Redhill Biopharma (STU:2RH) has a Net Income (Continuing Operations) of €-6.95 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Redhill Biopharma and its competitors.
Is Redhill Biopharma's Net Income (Continuing Operations) too high?
Redhill Biopharma's current Net Income (Continuing Operations) is €-6.95 Mil. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's Net Income (Continuing Operations) compare to CVSI and BUDZ?
Redhill Biopharma's Net Income (Continuing Operations) of €-6.95 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Redhill Biopharma and its competitors. Redhill Biopharma's current Net Income (Continuing Operations) is €-6.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current Net Income (Continuing Operations) of €-6.95 Mil. The current Net Income (Continuing Operations) is €-6.95 Mil. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current Net Income (Continuing Operations) is €-6.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Other Exchanges RDHL:USA
Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score

Get the complete analysis for STU:2RH

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24
Price